Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...

The global diabetes injection pens market is projected to grow at a CAGR of approximately 7% through 2028. Market expansion ...

The FDA has cleared a mobile application that will connect with a next-generation multiple daily injection automated insulin ...

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) ...

In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Dealing with cold weather may trigger a stress response. One of the ways in which our bodies naturally combat this is to ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- ...